Colorectal Cancer Screening Explained: Colonoscopy, FIT, and What Comes Next

Despite decades of public health messaging and clear evidence supporting the benefits of screening, colorectal cancer screening rates in the United States remain below national targets. During Colorectal Cancer Awareness Month, gastroenterologists are emphasizing both the progress made and the work that still lies ahead to improve early detection of colorectal cancer.

National initiatives have long aimed for screening rates of 80%, but uptake continues to fall just short of that benchmark. Current estimates generally place screening participation somewhere in the mid-to-high 70% range, with significant variation depending on the population and data source. According to Renee Williams, MD, an associate professor in the department of medicine at NYU Langone, those numbers highlight both success and persistent gaps in prevention efforts.

“We've had this 80% goal for a very long time, but we’re not fully there,” Williams said.

A key component of effective screening is understanding patient risk. Family history remains one of the most important factors guiding screening decisions. Patients with a first-degree relative diagnosed with colorectal cancer are considered higher risk and should undergo colonoscopy rather than noninvasive tests.

For average-risk individuals, however, several screening options are available. Noninvasive stool-based tests, including fecal immunochemical testing (FIT), offer a convenient alternative for patients who may be reluctant to undergo colonoscopy. For clinicians, Williams says the guiding principle is simple: the most effective screening test is the one the patient actually completes.

Still, she stresses that colonoscopy remains essential in many situations. Patients presenting with symptoms such as rectal bleeding, unexplained weight loss, or abdominal pain should undergo diagnostic colonoscopy rather than screening tests. Similarly, Williams says those with elevated risk due to family history are generally not appropriate candidates for stool-based screening.

Barriers to screening are complex and multifactorial. Access to care, limited patient awareness, and anxiety about testing all play a role. Many patients may also be unaware of their family history or individual risk factors. Because of this, Williams emphasized the importance of clinician-patient conversations about screening and prevention.

System-level strategies can also make a measurable difference. Research has shown that patient navigation programs and mailed screening outreach, such as sending FIT kits directly to patients, can significantly improve screening rates, particularly in vulnerable populations.

Looking ahead, Williams says emerging technologies could reshape the screening landscape. Blood-based screening tests are generating excitement because of their simplicity, but their role within existing screening strategies is still being defined. At the same time, researchers are exploring more personalized approaches that use risk models to tailor screening methods to individual patients.

National Colorectal Cancer Roundtable. Colorectal Cancer Is A Major Public Health Problem. August 5, 2025. Accessed March 9, 2026. 

https://nccrt.org/our-impact/data-and-progress/

May F. The Nuances of Noninvasive Screening for Colorectal Cancer, with Fola May, MD, PhD. HCPLive. April 22, 2025. Accessed March 9, 2026. 

https://www.hcplive.com/view/the-nuances-noninvasive-screening-colorectal-cancer-with-fola-may-md-phd

Videos

Williams explains colorectal cancer screening options, persistent barriers to uptake, and strategies to improve screening rates.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Colorectal Cancer Screening in 2026: Progress, Gaps, and What Comes Next, With Renee Williams, MD

Using Lower Quality Kidneys to Reduce Costs, Increase Transplants for Older Adults, With Matthew Kaufmann, PhD

Using typically discarded, higher-risk, yet acceptable-quality kidneys to increase transplant rates by 25% in adults ≥ 65 years of age may be cost-effective or even cost-saving, according to a new economic evaluation of the deceased donor transplant process.

In addition to the economic benefits, offering older adults the chance to utilize a kidney with a high kidney donor profile index (KDPI) >85% may be associated with reduced adverse waiting list events, including death, along with increased survival, and improved health-related quality-of-life (HRQOL).

How Can Higher KDPI Kidneys be Beneficial for Older Adults?

“There's this paradox where there's this really long wait list for kidney transplants, but approximately 1 in 4 recovered donor kidneys end up going unused,” study investigator Matt Kaufmann, PhD, Midwest Analytics and Disease Modeling Center Postdoctoral Fellow, explained in an interview for 

Then subsequently, there was a study that found that 62% of the kidneys that go unused in the US would have been allocated under France's allocation system.”

Within the US allocation system, approximately 20% of deceased donor kidneys are discarded each year. Specifically, >50% of those with a KDPI > 85 are discarded. In most clinical cases, when compared with staying on dialysis, even a KDPI = 99 kidney is suggested to offer improved longevity to transplant candidates.

To address this gap, investigators selected a synthetic cohort of adult candidates ≥ 65 years of age with end-stage kidney disease (ESKD) on the transplant waiting list, a patient population with markedly reduced rates of transplants compared to those <65 years of age.

“One study found that older candidates had expressed a willingness to trade off kidney quality for shorter waiting times,” said Kaufmann. “We have this pool of potentially usable kidneys that will otherwise go unused, and a patient population that receives a disproportionately low share of kidney transplants that may be willing to accept lower quality kidneys. We thought it was logical to estimate the benefits of allowing older candidates access to lower but acceptable quality kidneys.”

Assessing the Cost-Effectiveness and Utility of Lower Quality Kidneys

To assess the cost-effectiveness of increasing the kidney transplantation rate among older patients with ESKD by using acceptable-quality deceased donor kidneys, Kaufmann and colleagues conducted an economic evaluation using a discrete-time microsimulation model.

They included patient and caregiver time (opportunity) costs for a modified health care sector perspective analysis. Investigators calculated caregiver time costs as the mean number of hours per month spent caregiving multiplied by mean wage estimates from the Bureau of Labor Statistics, and assumed all candidates had a caregiver. They likewise calculated patient time costs for the time spent receiving care.

They derived age and sex specific HRQOL weights after transplant, as well as age, sex, and time-since-transplant specific after transplant. To evaluate hypothetical policies, they simulated an increased transplantation rate with a shift in the distribution of kidney quality due to the use of lower-quality but still acceptable-quality donor kidneys.

Considering the status quo of 0% increase in transplantation rates, investigators examined policies that would increase the transplantation rate by 5%, 10%, 15%, 20%, or 25%. An assumption was made that upon implementation of these policies, the average quality of deceased donor kidneys would decline to closely resemble the distribution of kidney quality as measured by the KDPI used in France’s system. Thus, the KDPI distribution under the policies reflects an increased use of high-KDPI donor kidneys. Investigators conducted scenario analyses around the proportion of donor kidneys where they increased the KDPI in 5% increments for up to 20% of donor kidneys.

As for statistical analysis, the primary outcomes include discounted lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). They evaluated the cost-effectiveness of interventions using a $100 ,000 per QALY gained willingness-to-pay (WTP) threshold.

Clinically, investigators found an association between deceased donor transplantation rate with a substantially decreased deaths on the waiting list and decreased waiting list removals as well as increased total net number of people undergoing transplants. Additionally, using lower-quality donor kidneys was associated with an increased risk of delayed graft function (DGF), but reduced wait times were associated with a decrease in this risk.

At a 5% increase in transplant rate, the DGF rate increased from the status quo. However, as the rate increased to 25%, the DGF rate moved back toward the status quo because of offsetting risk factors, a recurring pattern for the graft failure rate. Although lower kidney quality was associated with an increased risk of graft failure, reduced pretransplant dialysis time had a protective association.

The scenario analysis revealed that even if as many as 20% of transplanted kidneys were of lower quality than their given KDPI, increasing the transplantation rate by 25% would still be associated with 141 (range, 118-161) averted waiting list deaths and 375 (range, 350-396) waiting list removals per 10,000 candidates and 175 (range, 25-385) additional DGF cases and 103 (range, 9-266) additional graft loss events per 10,000 recipients.

Economically, when transplantation rates were increased by 25%, investigators noted an improvement in HRQOL cost-effectively, along with the most QALYs and lowest costs.

From the health care sector perspective, this would cost $8100 (95% credible interval [CrI], $700 to $141,00) per QALY gained. Notably, smaller increments of increased transplant rates cost more per QALY gained. Investigators believe smaller increases would mean fewer people undergo transplants, along with an increased mean time to transplant, which can result in additional adverse outcomes and costs.

Compared with the status quo, investigators observed a gain of 0.56 QALYs (95% CrI, 0.35 to 0.90 QALYs) and savings of $10,200 (95% CrI, $3400 to $17,900) for older adults.

Even for individuals ≥ 75 years of age, increasing deceased donor transplants by 25% was associated with HRQOL gains and cost $7800 (95% CrI, $1300 to $14,500) per QALY gained.

At a WTP threshold of $100,000 per QALY gained, choosing the status quo as opposed to the 25% increase transplantation rate was predicted to result in an expected loss of $51,400 per person, for a total of $886 million, from the health care sector perspective, and $58,300 per person, for a total of $1 billion, from the modified health care sector perspective.

While the study did not consider the downstream effects of new policies on younger candidates, investigators noted they would expect to see younger candidates benefit from shorter waiting times for all candidates.

Kaufmann MB, Tan JC, Owens DK, Chertow GM, Goldhaber-Fiebert JD. Cost-Effectiveness of Acceptable-Quality Deceased Donor Kidneys for Transplant in Older Candidates. 

https://doi.org/10.1001/jamanetworkopen.2025.55428

Friedewald JJ, Schantz K, Mehrotra S. Kidney organ allocation: reducing discards. 

https://doi.org/10.1097/mot.0000000000001049

An economic model suggest using lower quality, but acceptable kidneys for older adults may be cost efficective and clinically valuable.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Nicole Ramsey, MD, PhD, assistant professor of pediatrics in the division of pediatric allergy and immunology at the Icahn School of Medicine at Mount Sinai.

Race-Neutral Spirometry May Improve Diagnostic Accuracy, With Nicole Ramsey, MD, PhD

Using race-neutral reference equations to interpret 

 may improve diagnostic accuracy and reduce disparities in respiratory care, according to Nicole Ramsey, MD, PhD, assistant professor of pediatrics in the division of pediatric allergy and immunology at the Icahn School of Medicine at Mount Sinai.

On March 2, 2026, at the American Academy of Allergy, Asthma, & Immunology (AAAAI) annual meeting in Philadelphia, Ramsey presented the session, “Using Race-Neutral Spirometry Equations Improves Diagnostic Accuracy.” She discussed the clinical implications of shifting away from race-adjusted spirometry equations, which is an approach historically used in pulmonary function testing. She emphasized that clinicians should consider adopting race-neutral reference equations, such as those derived from the Global Lung Function Initiative (GLI), to interpret spirometry results more consistently across patient populations.

“The main takeaway message from my session is that physicians should be using race-neutral reference equations to interpret their spirometry,” Ramsey told 

 “Whether that has to do with using the mixed equation from the GLI 2012 reference equations or just using the GLI ’22 or July global equations, they will improve diagnostic accuracy if they use those equations.”

Spirometry remains a foundational tool for diagnosing and monitoring obstructive and restrictive lung diseases, including conditions such as asthma and chronic obstructive pulmonary disease (COPD). Traditional interpretation of spirometry results has relied on race-specific correction factors, which adjust predicted lung function values based on racial categories. However, Ramsey noted that this approach is increasingly questioned because race is a social construct rather than a biological determinant of lung function.

Race-neutral equations aim to address this limitation by applying the same reference standards to all individuals. According to Ramsey, removing race-based adjustments can improve diagnostic accuracy by preventing misclassification of lung disease severity.

In particular, the shift may have meaningful implications for patients who identify as Black. Ramsey explained that race-adjusted spirometry equations can sometimes produce falsely normal interpretations, potentially delaying diagnosis or masking clinically meaningful impairment. Spirometry results influence a wide range of clinical and administrative decisions, including treatment selection, disability assessments, and referral for advanced interventions such as lung transplantation.

Ramsey highlighted how race-adjusted equations can lead to differences in treatment classification. For example, two children, 1 Black and 1 White, with identical symptoms and pulmonary function measurements could be categorized differently when race-specific equations are used. In some cases, the White child might be classified as having moderate impairment, while the Black child might be categorized as having only mild impairment.

“What that could potentially mean is that the White child would get better or more comprehensive treatment,” Ramsey explained. “The Black child might not receive treatment as quickly, which could lead to more long-standing detrimental effects from asthma.”

Reanalysis of existing datasets also suggests that race-neutral spirometry could alter eligibility for disability benefits. Ramsey noted that analyses indicate Black and Asian veterans with COPD may have been undercompensated when disability assessments relied on race-adjusted lung function thresholds. In some cases, monthly disability payments could differ by as much as $3000 when race-neutral equations are applied.

Modeling studies suggest the interpretation change could influence transplant referral timelines. Analyses of population datasets have estimated that Black patients could qualify for lung transplant listing sooner when race-neutral spirometry equations are used, potentially shortening wait times by several weeks in some scenarios.

Ramsey acknowledged that the transition to race-neutral spirometry may produce unintended consequences. For example, certain professions that rely on spirometry thresholds, such as firefighting or military service, could see eligibility criteria shift for some individuals if race-neutral reference standards are adopted without broader policy adjustments.

“Race-neutral reference equations are not perfect,” Ramsey said. “But because race-adjusted equations falsely consider race a biological concept, they’re the best thing that we have…they improve diagnosis… and [help patients] get to care faster.”

Ramsey, N. Using Race-Neutral Spirometry Equations Improves Diagnostic Accuracy. Session presented at the 2026 American Academy of Allergy, Asthma, & Immunology in Philadelphia on March 2, 2026.

Using race-neutral spirometry equations such as GLI 2012 and GLI 2022 may improve diagnostic accuracy and reduce disparities in lung disease assessment.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 with bimekizumab led to significant improvements in patients’ International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes during the BE HEARD I and II studies.

These data on patients with HS and their IHS4 outcome improvements following bimekizumab therapy were authored by such investigators as Thrasyvoulos Tzellos, MD, PhD, a dermatologist in Norway at Nordland Hospital Trust. Tzellos and coauthors highlighted bimekizumab’s design as a humanized monoclonal immunoglobulin G1 (IgG1) antibody, selectively inhibiting interleukin (IL)-17F as well as IL-17A.

The team also described IHS4 as a validated clinician-rated tool.

 It includes draining tunnels to evaluate HS severity and can be implemented in routine clinical practice as well as clinical trials.

“While IHS4 assesses all key HS lesions, it places the greatest weight on draining tunnels, allowing the differences in efficacy of novel drug treatments in reducing HS severity to be observed,” the investigators wrote.

 “Here, the efficacy of bimekizumab in reducing HS severity, measured using IHS4 outcomes, is reported in patients with moderate to severe HS over 1 year in BE HEARD I and II.”

In the phase 3 BE HEARD I and BE HEARD II studies, Tzellos et al used a randomized, double-blind, placebo-controlled, multi-center trial design. They conducted their research between March 2020 - September 2022, carrying out their analyses via pooled data from both studies. Each study consisted of a 16-week placebo-controlled induction phase, and this was followed by a 32-week maintenance period, for a total duration of 48 weeks.

In the initial treatment phase, Tzellos and colleagues assigned participants in a 2:2:2:1 ratio to 1 of 4 groups: bimekizumab 320 mg provided every 2 weeks (Q2W) through Week 48; bimekizumab 320 mg every 4 weeks (Q4W) through Week 48; bimekizumab 320 mg Q2W through Week 16 followed by 320 mg Q4W through Week 48; or placebo through Week 16 followed by bimekizumab 320 mg Q2W through Week 48. Their eligibility criteria for the study were published previously.

Across both studies, there were 1014 individuals included in the analysis. Baseline disease severity, assessed by the IHS4, indicated substantial disease burden among subjects. Mean (standard deviation [SD]) IHS4 scores for those placed in the bimekizumab arms ranged from 33.4 (25.4) in the Q2W/Q2W group to 36.0 (34.0) in the Q2W/Q4W group, compared with 30.6 (21.8) in the placebo group. By the 16-week mark, Tzellos and coauthors found those treated with bimekizumab showed greater reductions in IHS4 scores from baseline than those receiving placebo.

Mean (SD) decreases ranged from −17.2 (24.8) in the Q4W/Q4W group to −17.8 (21.1) in the Q2W/Q2W cohort, whereas the placebo cohort were shown to have a diminished reduction of −6.1 (16.3). At the study’s point of entry, the proportion of those classified as having severe HS was high, ranging from 83.7% in the Q2W/Q2W arm to 88.4% in the Q2W/Q4W arm.

 By the 48-week mark, Tzellos et al noted a decline in this proportion by approximately half across treatment arms, falling to between 28.6% among individuals who transitioned from placebo to bimekizumab Q2W and 34.3% in the Q2W/Q2W cohort.

In addition, the percentage of individuals attaining an IHS4 score of 0 by Week 48 ranged from 23.7% in the Q2W/Q4W group to 26.7% among those who initially were given a placebo before switching to bimekizumab. Treatment via bimekizumab also resulted in increased response rates at multiple IHS4 improvement thresholds by Week 16.

 Greater proportions of subjects on active therapy achieved IHS4-55, IHS4-75, IHS4-90, and IHS4-100 compared with those assigned to placebo. From the 16 through 48-week marks, however, Tzellos and coauthors noted improvements became more similar across treatment groups as those originally assigned to placebo began receiving bimekizumab.

Consistent with these data, lesion counts were shown to be lower in the bimekizumab groups than in the placebo group at the 16-week mark, though by Week 48 lesion numbers were comparable among all study groups.

“The promising improvements seen with bimekizumab treatment highlight an opportunity to address the need for effective treatments against draining tunnels,” the team concluded.

Tzellos T, Giamarellos-Bourboulis EJ, Zouboulis CC, et al. Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II. J Eur Acad Dermatol Venereol. 2026 Feb 14. 

Zouboulis CC, Tzellos T, European Hidradenitis Suppurativa Foundation Investigator Group, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017 Nov;177(5):1401-1409. doi: 10.1111/bjd.15748. Epub 2017 Oct 30. PMID: 28636793.

Articles

Pooled phase 3 BE HEARD I/II data showed bimekizumab (dual IL‑17A/IL‑17F blockade) produced clinically meaningful reductions in HS severity by IHS4, a tunnel-weighted clinician score suited to trials and practice. Among 1014 patients with high baseline burden (mean IHS4 ~33–36; predominantly severe disease), bimekizumab achieved larger Week 16 IHS4 decreases versus placebo (≈−17 vs −6). Improvements were sustained through Week 48, halving severe HS proportions, with ~24%–27% reaching IHS4=0.

Bimekizumab was assessed using the International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in the BE HEARD I and II studies.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Bimekizumab-Treated Patients with HS See IHS4 Outcome Improvement Over 1 Year

Segment 2

The notion of “gradient reduction therapy,” originally articulated by James Udelson,MD, is presented as a logical next step in the management of oHCM.

In this video, Matthew Martinez, MD, raises the question of whether it is acceptable to leave patients with high resting or provocable LVOT gradients (eg, ≥130 mm Hg) if they appear asymptomatic and have preserved exercise capacity. Both he and Mariko Harper, MD, argue that although definitive outcomes data are not yet available, it is physiologically plausible that sustained severe obstruction promotes adverse remodeling, including progressive left ventricular hypertrophy, left atrial enlargement, mitral regurgitation, and myocardial fibrosis, all of which may increase long-term cardiovascular risk.

Harper emphasizes that emerging long-term data from mavacamten—the first FDA-approved cardiac myosin inhibitor—demonstrate favorable cardiac remodeling, with reductions in left ventricular mass, left atrial size, and systolic anterior motion of the mitral valve, as well as sustained biomarker improvement over several years. This experience suggests that earlier gradient elimination may have disease-modifying potential, though conclusive data on atrial fibrillation, heart failure events, and other hard outcomes are still pending. In parallel, both clinicians note the similarity to the evolution of aortic stenosis care, where earlier intervention has been associated with improved long-term outcomes as procedural risk declined.

Traditional agents, including β-blockers, non-dihydropyridine calcium channel blockers, and disopyramide, remain part of background therapy but no longer dominate the treatment algorithm in expert practice. Martinez explains that he still initiates these agents given their low upfront risk, but he no longer escalates to high doses or complex combinations before switching to a myosin inhibitor. Instead, he introduces a cardiac myosin inhibitor relatively early and, once gradient and symptoms improve, often de-escalates or discontinues background drugs. In this segment, Martinez and Harper present a nuanced, forward-looking view of gradient reduction as a primary therapeutic goal and outline how cardiac myosin inhibitors are displacing escalating polypharmacy with traditional negative inotropes.

Experts explore the concept of “gradient reduction therapy,” the remodeling effects of cardiac myosin inhibitors, and the evolving role of traditional agents in oHCM.

Video Series

Understanding Gradient Reduction Therapy and Cardiac Myosin Inhibitors in oHCM Care

Bernard Kadosh, MD, is the medical director of the ventricular assist device and cardiogenic shock programs at NYU Langone Health.

Kadosh and Gorodeski discuss 2 of the major challenges facing both patients and clinicians dealing with HF and how to address them.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Improving Heart Failure Awareness and GDMT Prescription, With Bernard Kadosh, MD, and Eiran Gorodeski, MD, MPH

New data suggest those who exhibit minimal early response to ruxolitinib cream may still achieve repigmentation with prolonged use extending to 2 years.


Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Prolonged Ruxolitinib Cream Effective for Vitiligo in Early Non-Responders

Anna Nowak-Wegrzyn, MD, PhD, of NYU Grossman School of Medicine.

At AAAAI 2026, Nowak-Wegrzyn presented FPIES diagnosis in infants, emphasizing clinical recognition and updated oral food challenge protocols.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

OFC Updates for FPIES in Infants, With Anna Nowak-Wegrzyn, MD, PhD

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

Hematology

The HCPFive: Top News for Healthcare Providers from the Week of 03/01

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The FDA approval of milsaperidone and a pair of positive trials in depression signal a month of progress in psychiatry.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

5 Psychiatry Headlines You Missed in February 2026

Karen Maddox, MD, MPH, is a professor of medicine and public health and co-director of the Center for Advancing Health Services, Policy & Economics Research at the Washington University School of Medicine.

Maddox discusses the AHA’s recent statement indicating that, should current trends continue, 6 in 10 US women will have cardiovascular disease by 2050.

Arrhythmia

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

6 in 10 US Women Predicted to Have Cardiovascular Disease by 2050, With Karen Maddox, MD, MPH

Barbara Gillespie, MD, is Chief Medical and Strategy Officer of the International Society of Glomerular Disease and Adjunct Professor at the University of North Carolina.

Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Strategic Alliance Partnership

Clinical Trial Summit 2026: Advanced Therapies, Equity, Global Outlook For Glomerular Diseases

The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.

PARASOL, Endpoints, and Rethinking Clinical Trials in Glomerular Disease

PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.

PLA2R, Membranous Nephropathy, and the PARASOL Membranous Project

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

Latest News

Colorectal Cancer Screening in 2026: Progress, Gaps, and What Comes Next, With Renee Williams, MD

Using Lower Quality Kidneys to Reduce Costs, Increase Transplants for Older Adults, With Matthew Kaufmann, PhD

Race-Neutral Spirometry May Improve Diagnostic Accuracy, With Nicole Ramsey, MD, PhD

Bimekizumab-Treated Patients with HS See IHS4 Outcome Improvement Over 1 Year

Understanding Gradient Reduction Therapy and Cardiac Myosin Inhibitors in oHCM Care